Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

RVC and Evgen Pharma to explore treatment for osteoarthritis
Researchers will investigate the potential of the drug SFX-01 as a treatment for osteoarthritis.
Work will build on a previous collaboration

The RVC and Evgen pharma have secured funding from the Biotechnology and Biological Sciences Research Council (BBSRC) for a four-year PhD studentship focused on investigating treatment for osteoarthritis.

The Industrial Co-operative Awards in Science & Technology (CASE) PhD Studentship will allow researchers to investigate the potential of the drug SFX-01 as a treatment for the disease, which affects almost 9 million people across the UK.

The work will build on a previous collaboration, which showed that mice with spontaneously-arising osteoarthritis demonstrated significantly improved bone architecture and preservation of normal movement following three months of SFX-01 treatment.

Professor Andrew Pitsillides, who led the study, said: “Myself and my colleagues Drs Isabel Orriss and Behzad Javaheri in the RVC’s Skeletal Biology Group are very excited by the prospect of working with Evgen Pharma to identify the cellular and molecular targets by which SFX-01 exerts its beneficial actions in osteoarthritis.”

Evgen Pharma is a clinical stage drug development company that focuses on the treatment of cancer and neurological conditions.

CEO Dr Stephen Franklin commented: “As a Company, we remain focused on the delivery of our current Company sponsored clinical trials and our strategic focus is in cancer and neurology. 

“We will, however, provide SFX-01 to a limited number of world leading academics and clinical groups that wish to investigate SFX-01 in alternative therapeutic areas if they can demonstrate a robust clinical plan, source their own non-dilutive grant funding and we retain commercialisation rights.

“We, and the RVC, are delighted that the BBSRC is funding this programme and it is another step towards the possibility of a future, grant funded, clinical trial on SFX-01 in osteoarthritis”. 

Become a member or log in to add this story to your CPD history

Campaign highlights ‘devastating impact’ of smoking around pets

News Story 1
 Leading vet charity PDSA has launched a campaign highlighting the ‘devastating impact’ that smoking can have on pets. The launch coincides with National No Smoking Day (14 March 2018) and aims to raise awareness of the risks of passive smoking and how to keep pets safe.

“Recent studies highlight that this is a really serious issue, and we want pet owners to know that they can make a real difference by simply choosing to smoke outdoors away from their pets,” said PDSA vet Olivia Anderson-Nathan. “We want pet owners to realise that, if they smoke, their pets smoke too.”  

Click here for more...
News Shorts
AWF named charity of the year

The Animal Welfare Foundation (AWF) has been chosen as charity of the year by the Veterinary Marketing Association (VMA). AWF is a vet-led charity, supported by the BVA, which aims to improve animal welfare though research funding, supporting veterinary education, providing pet care advice and encouraging debate on welfare issues.

VMA has pledged a range of support, including raising awareness and funds at their awards ceremony, which takes place on Friday 16 March, as well as offering marketing support through VMA marketing workshops.